Drugs / EX02 CAR-T
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06642025 | Sep 2024 → Aug 2026 overdue | acute myeloid leukemia | Zhimin Zhai | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EX02 CAR-T | “This is a early Phase 1 open-label, single-arm clinical study of EX02 CAR-T therapy for relapsed and refractory acute myeloid leukemia.” NCT06642025 ↗ |
| Modality | Cell therapy | “EX02 CAR-T therapy” NCT06642025 ↗ |
| Route | Intravenous | “intravenous injection of 1.0E6 CAR-T cells/kg” NCT06642025 ↗ |